复锐医疗科技(01696.HK)中期纯利升17.4%至1320.9万美元
格隆汇8月20日丨复锐医疗科技(01696.HK)公布,截至2019年6月30日止中期,公司实现收益8543.2万美元,同比增长9.3%;毛利4897.2万美元,同比增长17.0%;纯利1320.9万美元,同比增长17.4%;基本每股2.99美仙。
于期内,公司已建立全球销售及分销网络,上半年总收益较2018年同期增加9.3%,地域收益组合与上一报告期一样均衡的收益来自西部地区(北美及拉丁美洲),67.7%的收益来自东部地区(欧洲、中东及非洲地区及亚太地区)。毛利率为57.3%,而2018年同期为53.6%,毛利率增幅为17%,原因是直接销售额较分销商销售额高。
研发方面,研发雇员人数同比增长12.5%;公司推出了2款新产品:Soprano Titanium,这是目前市场上最先进的激光脱毛平台,风靡市场,激光脱毛产品线收益同比增长14.1%,及Colibri技术,一种细针微等离子体涂药器,专为非手术眼睑成形术及去皱而设计,深受市场欢迎。在临床研究方面,公司在整体治疗及女性健康领域开展了几项针对更安全、更有效的治疗的临床研究。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.